Despite medical cannabis being legalised in the UK in 2018, regulatory obstacles have hindered the roll out, leading to over 2% of the adult UK population self-prescribing a cannabis medicine from black-market sources.*
*2019 poll by YouGov for the Centre for Medicinal Cannabis

Despite medical cannabis being legalised in the UK in 2018, regulatory obstacles have hindered the roll out, leading to over 2% of the adult UK population self-prescribing a cannabis medicine from black-market sources.*
*2019 poll by YouGov for the Centre for Medicinal Cannabis

  • United Kingdom Overview
  • Materia in the UK
  • Partners & Associations

The UK implemented its medical cannabis law in November 2018, signifying the first time patients could obtain cannabis-based medicinal products (CBMPs) without one-off exemptions. Since then however, the market has struggled to develop, with only a few hundred prescriptions being written so far.

On the other hand, the CBD wellness market in the UK is evolving rapidly, with an increasing number of high street stores stocking a wide variety of CBD products, ranging from oils and capsules to vapes, edibles and drinks.

By October 2019 there were over 1.6 million regular users of CBD products in the UK*.

*Materia UK CBD Market Segmentation Report 2019

As UK physicians become acquainted with medical cannabis’ benefits and policymakers determine how to expand patient access, Materia has developed the infrastructure to import and distribute CBMPs, in preparation for the expansion of the UK medicinal market.

In the Wellness category, Materia’s UK team is focused on the manufacture and distribution of best-in-class CBD products, including partnering with established North American brands for market access. For more details on Materia Wellness, please head over to our wellness section.

Materia is a founding member of the Centre for Medicinal Cannabis (CMC), which is the UK’s leading industry membership body for businesses operating in the cannabis-based medicinal product market.